Methods of expanding embryonic stem cells in a suspension culture
US-2015252326-A1 · Sep 10, 2015 · US
US9404079B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9404079-B2 |
| Application number | US-201313909128-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 4, 2013 |
| Priority date | Aug 29, 2005 |
| Publication date | Aug 2, 2016 |
| Grant date | Aug 2, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of mainataining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.
Opening claim text (preview).
What is claimed is: 1. A method of expanding and maintaining human pluripotent stem cells in an undifferentiated state, the method comprising culturing the human pluripotent stem cells in a culture medium comprising a transforming growth factor beta 3 (TGFβ3) isoform— and factors that maintain and expand human pluripotent stem cells in an undifferentiated state, thereby expanding and maintaining the human pluripotent stem cells in the undifferentiated state. 2. The method of claim 1 , wherein said human pluripotent stem cells are human embryonic stem cells. 3. The method of claim 1 , wherein the human pluripotent stem cells are cultured in suspension. 4. The method of claim 1 , wherein the human pluripotent stem cells are cultured on a feeder-layer free matrix. 5. The method of claim 4 , wherein said feeder-layer free matrix is a fibronectin matrix. 6. The method of claim 1 , wherein the human pluripotent stem cells are cultured on feeder cells. 7. The method of claim 1 , wherein said TGFβ3 isoform is provided at a concentration of at least 0.5 ng/ml. 8. The method of claim 1 , wherein said TGFβ3 isoform is provided at a concentration of at least 2 ng/ml. 9. The method of claim 1 , wherein said culture medium further comprises basic fibroblast growth factor (bFGF). 10. The method of claim 9 , wherein said bFGF is provided at a concentration of at least 2 ng/ml. 11. The method of claim 1 , wherein said culture medium is serum-free. 12. The method of claim 1 , wherein said culture medium is devoid of animal contaminant. 13. The method of claim 3 , wherein said suspension is protein carrier-free.
Xeno-free medium · CPC title
Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies · CPC title
Basic fibroblast growth factor (bFGF, FGF-2) · CPC title
Vertebrate cells · CPC title
Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.